Phase 3 N=130 Randomized Double-blind Prevention

Evaluation of the Role of Magnesium in Prevention of AF Post Cardiac Surgery

Atrial Fibrillation (AF) · Magnesium Sulfate · Post Cardiac Surgery Patients

Bottom Line

View on ClinicalTrials.gov: NCT06675500 ↗

Enrolled (actual)

130

Serious AEs

23.1%

Results posted

Aug 2025

Primary outcome: Primary: Number of Participants With New Episodes of Atrial Fibrillation — 12; 27 participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Magnesium sulphate (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ain Shams University
Primary completion: Apr 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With New Episodes of Atrial Fibrillation	12; 27	—
SECONDARY Total ICU Length of Stay	2.1; 3.5	—
SECONDARY Total Ventilation Time	8.4; 7.8	—
SECONDARY Number of Participants With New Postoperative Renal Impairment	4; 9	—

Summary

Atrial fibrillation (AF) is a common complication after cardiac surgery. Most studies suggest that the frequency ranges between 25-40%. Some studies have shown that serum hypomagnesaemia is common after coronary artery bypass grafts (CABG) and other types of cardiac surgery and is associated with postoperative morbidity such as atrial tachyarrhythmia. The aim of the present study is to investigate the anti-arrhythmic effect of Magnesium Sulfate in prevention of atrial fibrillation post cardiac surgery.

Eligibility Criteria

Inclusion Criteria

• Elective open heart surgeries for coronary bypass grafting CABG,valvular lesion single or multiple replacement, combined CABG and valvular; with EF in preoperative echo is more than or equal 40%

Exclusion Criteria

Patients refuse to give informed consent.
Emergency open heart surgeries
Redo cases.
Patients with preoperative serum creatinine level ≥ 1.8 mg/dL
Patients with reduced intra/post operative urine output ≤ 1 ml/kg/hour.
Patients with Chronic Kidney disease, Renal failure on dialysis
Patients with rhythm defects as proved by ECG before administration of Mg/Placebo.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06675500). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.